Skip to main content
Contact Us
Subscribe
E-Edition
92°
Site search
Search
Menu
Open user controls
Log In Using Your Account
Log In
Don't have an account?
Sign Up Today
My Account
Dashboard
Profile
Saved items
Logout
Home
About Us
Contact Us
Advertise
Terms and Conditions
Privacy Policy
Home Delivery
Subscription Services
Place an Ad
Promote Your Event
Local Weather
News
Sports
Obits
Multimedia
Photo Galleries
Videos
e-Edition
Classifieds
Real Estate
Property For Rent
Cars & Vehicles
Jobs
Items For Sale
Pets
Auctions, Estate & Garage Sales
Services
Community
Personals
Place An Ad
Subscribe
Best of 2024
Archives
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Innate Pharma S.A. ADR
(NQ:
IPHA
)
2.507
-0.123 (-4.68%)
Streaming Delayed Price
Updated: 1:14 PM EDT, May 9, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Innate Pharma S.A. ADR
< Previous
1
2
3
4
Next >
Innate Pharma Announces Publication of Preclinical Data with a Trifunctional NK Cell Engager in Acute Myeloid Leukemia in Nature Biotechnology
January 16, 2023
From
Innate Pharma SA
Via
Business Wire
Sanofi and Innate Pharma Expand Collaboration for Natural Killer Cell Therapeutics in Oncology
December 19, 2022
From
Innate Pharma SA
Via
Business Wire
Innate Pharma Presents Data From Ongoing Phase 2 TELLOMAK Trial Demonstrating Clinical Activity of Lacutamab in Advanced Sézary Syndrome at ASH 2022
December 10, 2022
From
Innate Pharma SA
Via
Business Wire
Number of Shares and Voting Rights of Innate Pharma as of December 1, 2022
December 09, 2022
From
Innate Pharma SA
Via
Business Wire
Innate Pharma to present adenosine franchise, IPH5201 and IPH5301 at ESMO IO 2022
December 01, 2022
From
Innate Pharma SA
Via
Business Wire
Innate Pharma Reports Third Quarter Financial Results
November 14, 2022
From
Innate Pharma SA
Via
Business Wire
Innate Pharma Announces Conference Call and Webcast for Third Quarter 2022 Business Update
November 07, 2022
From
Innate Pharma SA
Via
Business Wire
Innate Pharma to Present Results From a Preliminary Analysis of the TELLOMAK Phase 2 Trial in Patients With Advanced Sezary Syndrome and ANKET™ Platform at ASH 2022
November 04, 2022
From
Innate Pharma SA
Via
Business Wire
Innate Pharma to Participate in Upcoming Investor Conferences
November 02, 2022
From
Innate Pharma SA
Via
Business Wire
Innate Pharma 2023 Financial Calendar
October 20, 2022
From
Innate Pharma SA
Via
Business Wire
Innate Pharma Presents Data From Ongoing Phase 2 TELLOMAK Trial Demonstrating Clinical Activity of Lacutamab in Advanced Mycosis Fungoides
September 23, 2022
From
Innate Pharma SA
Via
Business Wire
Innate Pharma Reports First Half 2022 Financial Results and Business Update
September 15, 2022
From
Innate Pharma SA
Via
Business Wire
Innate Pharma Announces Conference Call and Webcast for First Half 2022 Business Update
September 08, 2022
From
Innate Pharma SA
Via
Business Wire
Innate Pharma to Present Lacutamab PTCL Phase 1b Design and ANKET™ Platform at ESMO 2022
September 05, 2022
From
Innate Pharma SA
Via
Business Wire
Innate Pharma to Participate in Upcoming Investor Conferences
August 23, 2022
From
Innate Pharma SA
Via
Business Wire
Number of Shares and Voting Rights of Innate Pharma as of August 1, 2022
August 08, 2022
From
Innate Pharma SA
Via
Business Wire
Innate Pharma Provides Update on AstraZeneca-Sponsored INTERLINK-1 Phase 3 Study
August 01, 2022
From
Innate Pharma SA
Via
Business Wire
Innate Pharma to Participate in Upcoming Investor Conference
July 28, 2022
From
Innate Pharma SA
Via
Business Wire
Second Innate Pharma NK Cell Engager Selected by Sanofi as Drug Candidate for Development
July 21, 2022
From
Innate Pharma SA
Via
Business Wire
Innate Pharma to Participate in Upcoming Investor Conference
June 23, 2022
From
Innate Pharma SA
Via
Business Wire
Innate Pharma Announces IPH5201 Phase 2 Study in Lung Cancer
June 03, 2022
From
Innate Pharma S.A.
Via
Business Wire
Outcome of Innate Pharma’s 2022 Annual General Meeting
May 20, 2022
From
Innate Pharma S.A.
Via
Business Wire
Innate Pharma to Participate in Upcoming Investor Conferences
May 11, 2022
From
Innate Pharma SA
Via
Business Wire
Innate Pharma Reports First Quarter 2022 Financial Results and Business Update
May 10, 2022
From
Innate Pharma SA
Via
Business Wire
Number of Shares and Voting Rights of Innate Pharma as of May 1, 2022
May 10, 2022
From
Innate Pharma SA
Via
Business Wire
Innate Pharma Establishes an At-The-Market (“ATM”) Program on Nasdaq
May 03, 2022
From
Innate Pharma SA
Via
Business Wire
Innate Pharma Announces Conference Call and Webcast for Q1 2022 Business Update
May 03, 2022
From
Innate Pharma SA
Via
Business Wire
Innate Pharma: First Patient Dosed in Monalizumab Phase 3 Lung Cancer Clinical Trial Triggers $50M Payment From AstraZeneca
April 29, 2022
From
Innate Pharma SA
Via
Business Wire
Innate Pharma to Hold Its Annual General Meeting of Shareholders on May 20, 2022
April 08, 2022
From
Innate Pharma SA
Via
Business Wire
Innate Pharma Files Its 2021 Universal Registration Document (Document d’enregistrement universel) and 2021 Annual Report on Form 20-F
April 05, 2022
From
Innate Pharma SA
Via
Business Wire
< Previous
1
2
3
4
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.